Conclusion and Implications:
Significant proarrhythmic risk is predicted for hydroxychloroquine and
chloroquine at doses proposed to treat COVID-19. Clinicians should
carefully consider the risk of such treatments, and implement long term
QT interval monitoring in trials, particularly in patients with
electrolyte imbalances.